<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272569</url>
  </required_header>
  <id_info>
    <org_study_id>ISM01</org_study_id>
    <nct_id>NCT02272569</nct_id>
  </id_info>
  <brief_title>STARflo European Safety and Efficacy Study</brief_title>
  <official_title>A Prospective, Non-comparative, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the STARflo Glaucoma Implant in Patients With Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iSTAR Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iSTAR Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Non-comparative, Multi-center clinical trial to evaluate the safety and efficacy
      of the STARflo Glaucoma Implant in patients with refractory open angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter clinical trial to assess the efficacy and the safety of
      the STARflo™ Glaucoma Implant.

      Patients will enter the study after providing written informed consent. Patients will be
      screened to confirm that they are eligible for study participation.

      When eligibility has been established using the in/exclusion criteria, surgery will be
      scheduled.

      Pre and post-surgery, patients will be evaluated at scheduled intervals (1 day, 1 week, 1
      month, 3 months, 6 months, 12 months, 24 months) for a total duration of 24 months following
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in mean diurnal intraocular pressure (IOP) at 12 months vs. baseline IOP</measure>
    <time_frame>12 months</time_frame>
    <description>IOP of each patients at baseline will be compared to IOP of patient after 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in mean diurnal intraocular pressure (IOP) at 24 months vs. baseline IOP</measure>
    <time_frame>24 months</time_frame>
    <description>IOP of each patients at baseline will be compared to IOP of patient after 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in number of IOP lowering medications at 12 months vs. baseline</measure>
    <time_frame>12 months</time_frame>
    <description>compare number of active ingredient of each patients at baseline vs number of active ingredient after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in number of IOP lowering medications at 24 months vs. baseline</measure>
    <time_frame>24 months</time_frame>
    <description>compare number of active ingredient of each patients at baseline vs number of active ingredient after 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>assessment and counting of adverse events (% by adverse event) including procedure related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>comparison of visual acuity at 12 months vs. baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute success rate (%) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>absolute success: IOP &lt; 21mmHg and &lt; 5mmHg with a minimum of 30% IOP reduction compared to baseline without the need for concomitant glaucoma medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualified success rate (%) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>qualified success: IOP &lt; 21mmHg and &lt; 5mmHg with a minimum of 30% IOP reduction compared to baseline with and without the need for concomitant glaucoma medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualified success rate (%) at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>qualified success: IOP &lt; 21mmHg and &lt; 5mmHg with a minimum of 30% IOP reduction compared to baseline with and without the need for concomitant glaucoma medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute success rate (%) at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>absolute success: IOP &lt; 21mmHg and &lt; 5mmHg with a minimum of 30% IOP reduction compared to baseline without the need for concomitant glaucoma medication</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>STARflo Glaucoma Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STARflo Glaucoma Implant</intervention_name>
    <description>Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.</description>
    <arm_group_label>STARflo Glaucoma Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosis of refractory open angle glaucoma

          -  Documented 21 mmHg &lt; IOP ≤ 40 mmHg, under medication

          -  Patient must provide written informed consent

        Main Exclusion Criteria:

          -  Patients with diagnosis of glaucoma other than open angle glaucoma (e.g. angle closure
             glaucoma) in the study eye

          -  Patients who failed one or more cilio ablative procedure in the study eye if these
             cilio ablative procedures were performed as a consequence of previous failed filtering
             surgery

          -  Clinically significant intra-ocular inflammation or infection, presence of ocular
             disease such as uveitis, ocular infection, severe dry eye, severe blepharitis, active
             proliferative/inflammatory retinopathy in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zubair Hussain, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor Representative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng Lim, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Advisor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Central Onco Hospital</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69417</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHNO des Quinze Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik Universitatsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik fur Augenheilkunde Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>glaucoma drainage device</keyword>
  <keyword>glaucoma shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

